2cureX AB (publ) (STO:2CUREX)
Sweden · Delayed Price · Currency is SEK 1.700
-0.060 (-3.41%)
Jun 11, 2026, 3:39 PM CET
2cureX AB Earnings Call Transcripts
Fiscal Year 2026
-
A strategic shift is underway toward a comprehensive precision medicine platform, leveraging tumor preservation, U.S. expansion, and key partnerships to drive growth. Regulatory advantages and data generation are central to value creation, with recurring revenue expected from a shared diagnostic platform.
Fiscal Year 2024
-
Two new board members were elected to drive a transformation, including a shift to a direct-to-patient commercial model and the sale of the Danish-German subsidiary. The company is preparing for IVD-R certification and plans to scale operations, with proceeds from the asset sale to be distributed to shareholders.